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H
epatitis B virus (HBV) infection in patients 
with  end-stage  renal  disease  (ESRD)  on 
renal  replacement  therapy—hemodialysis  and/or 
renal  transplantation—usually  has  an  unfavorable 
course with a tendency towards chronicity leading to 
increased morbidity and mortality (1). Furthermore, 
the patients with the infection remain a source of 
nosocomial infection during hemodialysis. Though 
the  incidence  of  HBV  infection  in  patients  with 
ESRD has significantly decreased due to preventive 
measures like vaccination and obedience to universal 
precaution  and  isolation  rules  during  dialysis, 
this infection still continues to occur during renal 
replacement  therapy  in  many  units  in  the  world 
including  India.  Patients  with  ESRD  remain  at 
increased  risk  of  contracting  HBV  because  of 
increased  exposure  to  blood  products,  shared 
hemodialysis equipment, frequent breaching of the 
skin, immunodeficiency of Chronic Kidney Disease 
(CKD),  and  continuing  high  prevalence  rates  of 
HBV  infection  among  hemodialysis  patients. The 
frequency of HBV seropositivity in renal replacement 
therapy in India had been reported from 4% to 44% 
(2-4). Higher frequencies are reported only from few 
units, while in most of the larger well-organized units, 
it is less than 5%. Patients with ESRD regularly get 
transplant unless they have significant histological 
fibrosis  or  clinically  advanced  liver  disease.  We 
had earlier reported that chronic liver disease, due 
to  hepatitis,  was  the  second  most  common  cause 
of death in renal transplant patients in the second 
decade post-transplant (5).
Universal  precautions  are  the  most  accepted 
method for prevention of blood-borne infections in 
hemodialysis program, though it is easier said than 
done. Many units could not demonstrate decrease in 
the rate of blood-borne infection while claiming to 
follow universal precautions. Obviously, there is gap 
between knowing the principles of the precautions and 
implementing them in day to day practice. In various 
types of blood-borne infections, HBV infection has 
a different scenario than others like hepatitis C virus 
(HCV) and human immunodeficiency virus (HIV) 
infection. HBV prevention is possible by vaccination 
and abiding to universally-accepted approaches to 
isolation of patients as compared to no vaccine and 
controversy of isolation of HCV and HIV patients. 
In our center, the prevalence of HBV infection was 
0% until 2005. The rate increased to 1.9% in 2006, 
3.3%  in  2007,  3%  in  2008,  4.6%  in  2009  and 
13.7% in June 2010. The incidence rate was less than 
2% per year. Therefore, in many units, patients on 
maintenance dialysis are still contracting new HBV 
infections and we need to be more careful about it. 
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These patients require double dose of HBV vaccine 
(40 µg—20 µg in each deltoid muscles) scheduled at 
0, 1, 2, and 6 month. Many physicians still continue 
to give three doses and all the 40 µg injected in a 
single deltoid despite clear mentioning of the dosage 
and  schedule  by  the  treating  nephrologist.  This 
requires  awareness  amongst  non-nephrologists  as 
large  number  of  pre-dialysis  patients  with  CKD 
get follow-up by physicians. Furthermore, not only 
physicians but also many nephrologists do not bother 
for assessing anti-HBs titer after vaccination to be 
sure of protection against HBV. Recently, I have seen 
new HBV infection developing in patients following 
renal transplantation suggesting that although they 
received  transplants,  they  were  still  unprotected 
against HBV. Even when we get adequate vaccination, 
patients  with  CKD,  with  or  without  dialysis, 
experience lower seroconversion rates (32%–80%), 
lower peak antibody titers, and shorter durations of 
seroprotection (protective antibody titers maintained 
in 50% of patients with CKD compared with 85% of 
healthy individuals after one year). Therefore, these 
patients must be assessed by antibody titers regularly, 
probably once a year.
Strategies to improve the response rate among such 
patients include vaccination as early as possible in 
the course of CKD. Additional strategies to improve 
vaccination response though important, still remain 
not well adapted. These include use of adjuvants to 
vaccine formulations to enhance the immunogenicity 
of the antigens. Aluminum is one such predominant 
adjuvant used in many currently available vaccines, 
including  the  standard  HBV  vaccine.  Another 
adjuvant HB-AS04 has previously been demonstrated 
to have the ability to elicit higher and more persistent 
levels  of  anti-hepatitis  B  surface  antibodies  (anti-
HBs) in CKD patients, when compared with double 
doses of standard HBV vaccine. While never tested 
previously  in  CKD  patients,  HB-AS02  has  been 
shown to generate strong and persistent humoral and 
T-cell responses in healthy adults. The results of a 
recent meta-analysis also suggest significant benefits 
in the administration of levamizole as an adjuvant to 
HBV vaccine to increase seroprotection in patients 
with ESRD. Furthermore, in randomized controlled 
trial  settings,  both  intradermal  HBV  vaccination 
and the addition of granulocyte-macrophage colony-
stimulating factor (GM-CSF) have been shown to 
be better than standard HBV vaccination to generate 
a seroprotective antibody response. Our own study 
testing GM-CSF shows earlier protection with higher 
antibody  titer  in  pre-dialysis  patients  with  CKD 
(unpublished data). Moreover, these agents have been 
tested in cohorts comprising purely dialysis patients 
non-responsive to primary HBV vaccination. Each of 
these improvements has specific relevance to patients 
with CKD. Rapid seroconversion is clearly beneficial 
within the dialysis setting, as the sooner a protective 
antibody titer is obtained, the lower the cumulative 
risk of infection. The duration of protection afforded 
by HBV vaccination is directly proportional to the 
peak antibody level obtained after vaccination.
The impact of renal transplant and treatment with 
immunosuppressive drugs on patients with HBV is 
not very clear. Immunosuppressive therapy is known 
to modify the natural history of the hepatic disease 
due to the increase in viral replication (6), though the 
real impact on patients’ outcome in HBV-infected 
subjects does usually not become apparent in the 
initial few years of renal transplantation after which 
time liver failure is responsible for death in good 
number of cases (5). Interferon used for the treatment 
of HBV infection, has been shown to be effective in 
large number of cases but in renal transplant patients 
it is contraindicated, as its immunomodulatory effects 
can induce rejection episodes. Of the other drugs 
being  used  for  treatment  of  HBV,  the  maximum 
experience has been with Lamivudine—a synthetic 
nucleoside analogue with a potent action on HBV 
replication—with decreasing the progression of liver 
disease. Unlike interferon, Lamivudine does not have 
an immunomodulatory effect and therefore, could 
be safely used in renal transplant patients. We have 
recently published our experience of Lamivudine in 
these patients (7). Though Entecavir and Tenofovir 
are promising new drugs for HBV infection, which 
are  said  to  be  better  than  Lamivudine  for  naive 
patients, their use in renal transplant patients is still 
to be studied. Till then, Lamivudine will continue 
to  be  a  commonly  used  drug  in  these  patients. 
Our  experience  showed  that  although  HBV-PCR 
clearance is possible in nearly 50% of patients, HBe 
Ag and HBs Ag seroconversion is seen in very few 
patients. Enzyme normalization was seen in 77% of 
patients, though enzyme normalization is difficult to 
interpret in them, as many of these patients being 
immunosupprressed, may not show enzyme elevation 
in  spite  of  having  disease  activity  on  histology. 
Practically, in these patients, we probably have to 
depend on virological response for assessing therapy 
rather  than  response  to  enzyme  normalization. 
In  terms  of  number  of  patients,  our  study  is  by 
far  the  largest  number  of  patient  series  in  renal 
transplant for assessing role of Lamivudine in these 
patients. Duration of treatment with Lamivudine is 
controversial. Since last year or so, we have started 
using Tenofovir in HBV patients on dialysis followed 
by renal transplant. Our initial impression is that it 
is better in terms of clearing the viral load. However, 
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Tenofovir  and  follow-up  has  also  been  short  so 
making  a  definite  conclusion  is  premature.  Effect 
of treatment of HBV on patients in renal transplant 
setting in terms of liver outcome as well as outcome 
of transplant is not very well studies and reported. 
Our own study showed that the incidence of acute 
rejection  in  these  patients  is  not  different  from 
untreated patients. However, long-term impact on 
graft and patients survival has not been commented 
upon in most of the studies. Assessing the outcome of 
liver, truly requires repeated liver biopsy to document 
regression, if any, of histological staging and grading. 
However, these types of studies are also lacking and 
with significantly decreasing prevalence of HBV in 
renal transplant patients, and short of multicenter 
studies, this information is unlikely to be available 
in near future.
Treatment  of  HBV  infection  is  changing  with 
time. Unlike therapy with interferon which has a time 
bound schedule, duration of therapy with synthetic 
nucleoside analogues is not defined in either non-
renal transplant or renal transplant patients. With 
the availability of newer drugs like Entecavir and 
Tenofovir, which have become first line therapy in 
naive HBV infected patients, we are likely to use these 
drugs in renal transplant patients also. However, in 
transplant patients it is time, which will uncover the 
efficacy and tolerability of these drugs, as in most of 
the clinical trials on these drugs, transplant patients 
have been excluded so that currently we can hardly 
find any studies with these drugs on renal transplant 
patients.  Still,  the  best  approach  of  management 
of these patients is vaccination against HBV with 
adequate dosage and assessment of the effectiveness 
of the vaccine along with isolation of infected patients 
during hemodialysis.
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